Attached files
| file | filename |
|---|---|
| EX-32 - EX-32 - ImmunoGen, Inc. | ex-32.htm |
| EX-31.1 - EX-31.1 - ImmunoGen, Inc. | ex-31d1.htm |
| EX-21 - EX-21 - ImmunoGen, Inc. | ex-21.htm |
| EX-10.11(F) - EX-10.11(F) - ImmunoGen, Inc. | ex-10d11f.htm |
| EX-10.7(A) - EX-10.7(A) - ImmunoGen, Inc. | ex-10d7a.htm |
| EX-4.3 - EX-4.3 - ImmunoGen, Inc. | ex-4d3.htm |
| 10-K - 10-K - ImmunoGen, Inc. | imgn-20191231x10kd363eb.htm |
EXHIBIT 23
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
(1) |
Registration Statement (Form S-8 Nos. 333-138713, 333-147738, 333-155540, 333-170788, 333-185086, 333-215196, 333-225281, 333-225860, 333-235632 and 333-235633) of ImmunoGen, Inc., and |
|
(2) |
Registration Statement (Form S-3 Nos. 333-216438 and 333-223507) of ImmunoGen Inc.; |
of our reports dated March 11, 2020, with respect to the consolidated financial statements of ImmunoGen Inc. and the effectiveness of internal control over financial reporting of ImmunoGen Inc. included in this Annual Report (Form 10-K) of ImmunoGen Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 11, 2020